Literature DB >> 32285269

The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases.

.   

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of gastric cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.

Entities:  

Mesh:

Year:  2020        PMID: 32285269     DOI: 10.1245/s10434-020-08320-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  Staging laparoscopy in gastric cancer. Accuracy and impact on therapy.

Authors:  Valentin Muntean; Anca Mihailov; Cornel Iancu; Razvan Toganel; Ovidiu Fabian; Iacob Domsa; Maximilian Vlad Muntean
Journal:  J Gastrointestin Liver Dis       Date:  2009-06       Impact factor: 2.008

2.  Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named aqua dissection.

Authors:  Y Yonemura; A Elnemr; Y Endou; H Ishibashi; A Mizumoto; M Miura; Yan Li
Journal:  Gastroenterol Res Pract       Date:  2012-05-15       Impact factor: 2.260

  2 in total
  2 in total

Review 1.  Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.

Authors:  Yong Xiang Gwee; Daryl Kai Ann Chia; Jimmy So; Wim Ceelen; Wei Peng Yong; Patrick Tan; Chin-Ann Johnny Ong; Raghav Sundar
Journal:  J Clin Oncol       Date:  2022-06-01       Impact factor: 50.717

Review 2.  Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease.

Authors:  Hamza Khan; Fabian M Johnston
Journal:  J Surg Oncol       Date:  2022-06       Impact factor: 2.885

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.